← Oncology Approval Tracker

FDA DECISION ·

Rezlidhia

olutasidenib · Rigel Pharmaceuticals

FDA approvalNew therapyAcute myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory AML and a susceptible IDH1 mutation identified by an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

The action adds an IDH1-directed option for previously treated AML.

What research teams should watch

Confirm mutation testing and implement a plan to recognize and escalate differentiation syndrome.

PRIMARY RECORDS

Sources